Publications for Martin Henriksson
Co-author map based on ISI articles 2007-

Publications mentioned in social media 13 times*

Keywords

trial treatment strategy risk quality-adjusted prioritisation patients model health events estimated decision cost-effectiveness cost-effective coronary clinical cancer biomarkers artery 000

Journal Articles

Martin Henriksson, Elisabet Nikolic, Audun Ohna, Lars Wallentin and Magnus Janzon
  Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark
 
Altmetric usage: 3

  Scandinavian Cardiovascular Journal, 2014, 48(3), 138-147.

Elisabet Nikolic, Magnus Janzon, Ole Hauch, Lars Wallentin and Martin Henriksson
  Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study
 
Altmetric usage: 10

  European Heart Journal, 2013, 34(3), 220-228.
 Web of Science® Times Cited: 19

B Sigvant, Martin Henriksson, F Lundin and Eric Wahlberg
  Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
  EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION and REHABILITATION, 2011, 18(2), 254-261.
 Web of Science® Times Cited: 6

Swen-Olof Andersson, Ove Andren, Johan Lyth, Jennifer R Stark, Martin Henriksson, Hans-Olov Adami, Per Carlsson and Jan-Erik Johansson
  Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4)
  SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2011, 45(3), 177-183.
 Web of Science® Times Cited: 8

H Hemingway, Martin Henriksson, R. Chen, J. Damant, N. Fitzpatrick, K. Abrams, A. Hingorani, Magnus Janzon, M. Shipley, G. Feder, B. Keogh, Ulf Stenestrand, K. McAllister, J-C Kaski, A. Timmis, S. Palmer and M. Sculpher
  The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model.
  Health Technology Assessment, 2010, 14(9), .
 Web of Science® Times Cited: 8

Mikael Aasa, Martin Henriksson, Mikael Dellborg, Lars Grip, Johan Herlitz, Lars-Åke Levin, Leif Svensson and Magnus Janzon
  Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-Results of the Swedish Early Decision reperfusion Study (SWEDES) trial
  AMERICAN HEART JOURNAL, 2010, 160(2), 322-328.
 Web of Science® Times Cited: 6

Martin Henriksson, Jacqueline Damant, Natalie K Fitzpatrick, Keith Abrams, Aroon D Hingorani, Ulf Stenestrand, Magnus Janzon, Gene Feder, Bruce Keogh, Martin J Shipley, Juan-Carlos Kaski, Adam Timmis, Mark Sculpher and Harry Hemingway
  Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery
  BRITISH MEDICAL JOURNAL, 2010, 340, .
 Web of Science® Times Cited: 19

Martin Henriksson, David Epstein, Stephen Palmer, Mark Sculpher, Tim Clayton, Stuart Pocock, Robert Henderson, Martin Buxton and Keith A. A. Fox
  The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial
  Heart, 2008, 94, 717-723.
 Web of Science® Times Cited: 18

Thor-Henrik Brodtkorb, Martin Henriksson, Kasper Johannesen-Munk and Fredrik Thidell
  Cost-effectiveness of C-Leg compared to non microprocessor controlled knees: a modeling approach
  Archives of Physical Medicine and Rehabilitation, 2008, 89(1), 24-30.
   Fulltext  PDF  
 Web of Science® Times Cited: 12

Martin Henriksson, Fredrik Lundgren and Per Carlsson
  Cost-effectiveness of endarterectomy in patients with asymptomatic carotid artery stenosis in Sweden
  British Journal of Surgery, 2008, 95(6), 714-720.
 Web of Science® Times Cited: 15

Joakim Ramsberg and Martin Henriksson
  The cost-effectiveness of oral triptan therapy in Sweden
  Cephalalgia, 2007, 27(1), 54-62.
 Web of Science® Times Cited: 4

Martin Henriksson, Fredrik Lundgren and Per Carlsson
  The value of further research into the cost-effectiveness of endarterectomy in patients with asymptomatic carotid artery stenosis in Sweden
  , 2007, , .

Martin Henriksson and Kristina Burström
  Kvalitetsjusterade levnadsår och EQ-5D. En introduktion
  Läkartidningen, 2006, 103(21-22), 1734-1739.

Martin Henriksson, Fredrik Lundgren and Per Carlsson
  Informing the efficient use of health care and health care research resources: the case of screening for abdominal aortic aneurysm in Sweden
  Health Economics, 2006, 15(12), 1311-1322.
 Web of Science® Times Cited: 4

Martin Henriksson and Fredrik Lundgren
  Decision-anaytical model with lifetime estimation of costs and health outcomes for one-time screening for abdominal aortic aneursm in 65-year-old men
  British Journal of Surgery, 2005, 92(8), 976-983.
 Web of Science® Times Cited: 20

Martin Janson, Ingela Björholt, Per Carlsson, Eva Haglind, Martin Henriksson, Elisabeth Lindholm and Bo Anderberg
  Randomized clinical trial of the costs of open and laparoscopic surgery for colonic cancer
  British Journal of Surgery, 2004, 91(4), 409-417.
 Web of Science® Times Cited: 109

Karin Sennfält, Per Carlsson, Johan Thorfinn, Jessica Frisk, Martin Henriksson and Eberhard Varenhorst
  Technological changes in the management of prostate cancer result in increased healthcare costs: a retrospective study in a defined Swedish population
  Scandinavian Journal of Urology and Nephrology, 2003, 37(3), 226-231.
 Web of Science® Times Cited: 8

J Martikainen and Martin Henriksson
  Epävarmuuden hallinta taloudellisessa arvioinnissa - miten hallita epävarmuutta EVPI-analyysin avulla?
  Aiheita , 2003, 3, 43-46.

Books

Lars-Åke Levin, Karin Sennfält, Magnus Janzon, Martin Henriksson, Agneta Andersson and Lars Bernfort
  En introduktion i hälsoekonomi
  AstraZeneca Sverige AB, 2004.


Conference Articles

A Manca, P Saramago and Martin Henriksson
  INTEGRATING INDIVIDUAL PATIENT LEVEL RCT DATA WITH A COMPREHENSIVE DECISION ANALYTIC COST EFFECTIVENESS MODEL
  In VALUE IN HEALTHVolume 12, Issue 3, 2009.


Harry Hemingway, Ruoling Chen, Jacqueline Damant, Natalie Fitzpatrick, Aroon Hingorani, Bruce Keogh, Kate McAllister, Martin Henriksson, Keith Abrams, Magnus Janzon, Ulf Stenestrand, Juan-Carlos Kaski, Adam Timmis, Stephen Palmer and Mark Sculpher
  Cost-effectiveness of circulating biomarkers in managing stable coronary disease.
  SMDM,2008, 2008.


Martin Henriksson, Magnus Janzon, M. Aasa, Elisabet Lundborg (Nikolic), L. Svensson, J. Herlitz, L. Grip and Lars-Åke Levin
  Cost-effectiveness of very early treatment strategies for acute ST-elevation myocardial infarction based on the Swedish early decision (SWEDES) reperfusion trial (oral presentation)
  SMDM Europe,2008, 2008.


Nathalie Eckard, Martin Henriksson, Thomas Davidson, Håkan Walfridsson and Lars-Åke Levin
  Cost-effectiveness of catheter ablation versus antiarrhytmic drugs for patients with symptomatic atrial fibrillation (oral presentation)
  SMDM Europe,2008, 2008.


Joakim Ramsberg and Martin Henriksson
  The cost-effectiveness of antidepressant therapy in Sweden (oral presentation)
  SMDM Europe,2008, 2008.


Martin Henriksson, S. Palmer, Mark Sculpher, K. Abrams and H. Hemingway
  Cost-Effectiveness of circulating biomarkers in managing stable coronary artery disease
  SMDM,2008, 2008.


Martin Henriksson, David Eptein, Stephen Palmer and Mark Sculpher
  Pros and cons of event based modelling in economic evaluation (oral presentation)
  IHEA,2007, 2007.


Thor-Henrik Brodtkorb, Martin Henriksson, Kasper Johannesen-Munk and Fredrik Thidell
  Cost-effectiveness of C-Leg compared to non microprocessor controlled knees: a modelling approach (oral presentation)
  iHEA 2007, 6th Biennial World Congress,July 8-10, Copenhagen, Denmark, 2007.


Martin Henriksson, David Epstein, Steve Palmer and Mark Sculpher
  The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome
  Society for Medical Decision Making SMDM,2006, 2006.


Joakim Ramsberg and Martin Henriksson
  The cost-effectiveness of oral triptan therapy from a societal perspective using the best clinical evidence in a probabilistic model
  Health Technology Assessment International,2005, 2005.


Martin Henriksson and Joakim Ramsberg
  Cost-effectiveness of Strategies for Testing out Triptan Treatment on Migraine Patients
  Health Technology Assessment International,2005, 2005.


Martin Henriksson and Fredrik Lundgren
  Modelling the cost-effectiveness of screening for abdominal aortic aneurysm and assessing the value of further research
  IHEA,2005, 2005.


Martin Henriksson and Fredrik Lundgren
  Cost-effectiveness of screening 65 year old males for abdominal aortic aneurysm
  Health Technology Assessment International HTAi,2004, 2004.


Martin Henriksson, Anders Nordlund, Magnus Janzon and Eva Swahn
  A comparison of EQ-5D and SF-6D utilities
  iHEA 2003, San Francisco. Muntlig posterpresentation,2003, 2003.


Magnus Janzon, Martin Henriksson, Lars-Åke Levin and Eva Swahn
  Quality of life in unstable angina - Individual and public preferences differ in levels but are similar when measuring changes over time
  European Heart Journal, 2002.


Magnus Janzon, Martin Henriksson, Lars-Åke Levin and Eva Swahn
  Quality of life in unstable angina. Individual and public preferences differ in levels but are similar when measuring changes over time
  ISTAHC-konferens, Berlin, juni 2002,2002, 2002.


Ph.D. Theses

Thor-Henrik Brodtkorb
  Cost-effectiveness analysis of health technologies when evidence is scarce
  2010.


  Fulltext PDF

Martin Henriksson
  Cost-effectiveness and Value of Further Research of Treatment Strategies for Cardiovascular Disease
  2007.


  Fulltext PDF

Reports

Martin Henriksson and Fredrik Lundgren
  One-time Screening of Abdominal Aortic Aneurysm in 65-year-old Men
  2005.


Martin Henriksson and Fredrik Lundgren
  Screening för pulsåderbråck i buken - en hälsoekonomisk utvärdering
  2004.


* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.